Clover Health Investments, Corp.
NASDAQ:CLOV · NASDAQ Global Select
+$0.17 today
Vol 7.06M · Avg 7.31M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CLOV · Revenue to Net Income
Key Ratios
Analysis
$2.2B of revenue converted into -$56.9M of net income for the selected period. Gross margin is 18.0% and net margin is -3.4%, showing how much revenue survives after costs and taxes. EPS is $-0.11, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9B +40.3% | $1.4B +8.8% | $1.3B +15.0% | $1.1B -25.5% | $1.5B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.6B +55.9% | $1.0B +0.2% | $1.0B +1.2% | $993.1M -36.0% | $1.6B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $355.9M -2.4% | $364.8M +42.5% | $256.0M +147.3% | $103.5M +230.7% | -$79.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 18.5% -8.1pp | 26.6% +6.3pp | 20.3% +10.9pp | 9.4% +14.8pp | -5.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $176.3M -56.9% | $408.9M -7.1% | $440.2M -8.7% | $482.4M +8.2% | $445.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $441.4M +7.5% | $410.6M -11.0% | $461.3M +18.2% | $390.1M -30.1% | $557.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.7M +26.7% | $1.3M -47.0% | $2.5M +111.4% | $1.2M -4.7% | $1.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$83.9M -86.6% | -$44.9M +78.4% | -$207.6M +17.6% | -$252.0M +55.8% | -$569.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -4.4% -1.1pp | -3.3% +13.2pp | -16.5% +6.5pp | -23.0% +15.7pp | -38.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$85.5M -87.0% | -$45.7M +77.7% | -$205.3M +28.4% | -$286.7M +55.0% | -$637.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -4.4% -1.1pp | -3.3% +13.0pp | -16.3% +9.9pp | -26.1% +17.1pp | -43.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $7.0K -99.5% | $1.4M -91.9% | $16.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$20.0K +96.1% | -$517.0K +89.3% | -$4.8M -115.0% | $32.1M -34.8% | $49.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$85.5M -84.9% | -$46.3M +78.0% | -$210.1M +17.5% | -$254.6M +56.7% | -$587.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -4.4% -1.1pp | -3.4% +13.3pp | -16.7% +6.5pp | -23.2% +16.7pp | -39.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$85.5M -98.9% | -$43.0M +79.8% | -$213.4M +37.2% | -$339.6M +42.2% | -$587.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -4.4% -1.3pp | -3.1% +13.8pp | -16.9% +14.0pp | -31.0% +9.0pp | -39.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -93.6% | -$0 +80.5% | -$0 +36.6% | -$1 +43.2% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -93.6% | -$0 +80.5% | -$0 +36.6% | -$1 +43.2% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $517.2M +5.6% | $490.0M +1.6% | $482.2M +1.2% | $476.2M +1.1% | $470.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $517.2M +5.6% | $490.0M +1.6% | $482.2M +1.2% | $476.2M +1.1% | $470.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$5.34B
10x Genomics, Inc.
NASDAQ:TXG
$4.42B
LifeStance Health Group, Inc.
NASDAQ:LFST
$3.42B
National HealthCare Corporation
AMEX:NHC
$3.02B
Guardian Pharmacy Services, Inc.
NYSE:GRDN
$2.76B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.63B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.22B
QuidelOrtho Corporation
NASDAQ:QDEL
$898.91M
Certara, Inc.
NASDAQ:CERT
$891.23M
BGM Group Ltd.
NASDAQ:BGM
$74.69M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CLOV generate?
Clover Health Investments, Corp. (CLOV) reported $1.92B of revenue in fiscal 2025.
Is CLOV profitable?
Clover Health Investments, Corp. (CLOV) reported -$85,549,000.00 of net income, with a net margin of -4.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.